Physician profile
John Bello
NPI 1902110778
$8,355.56
in general payments reported to CMS, 2019-2025
33 companies · $949 in 2025
The $949 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $965 · 2020: $961 · 2021: $1,118 · 2022: $1,549 · 2023: $1,302 · 2024: $1,512 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,672 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $53.00 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,672.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53.00 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,114.59 | 2020-2025 | Cardiomems, Jot Dx, Aveir |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,014.16 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $834.29 | 2020-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $581.23 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $494.54 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.06 | 2019-2025 | Jardiance |
| Pfizer INC. | $328.34 | 2019-2025 | |
| Boston Scientific Corporation | $325.93 | 2019-2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $304.84 | 2020-2023 | Eliquis, Camzyos |
| Amgen INC. | $263.14 | 2019-2025 | Repatha |
| Edwards Lifesciences Corporation | $226.35 | 2019 | |
| Novo Nordisk INC | $180.53 | 2022-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $170.02 | 2021-2022 | |
| Esperion Therapeutics, INC. | $168.97 | 2021-2022 | |
| Daiichi Sankyo INC. | $157.25 | 2023-2024 | Injectafer |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $135.11 | 2019 | |
| Atricure, INC. | $99.65 | 2019-2024 | |
| Astellas Pharma US INC | $71.64 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $70.84 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $66.83 | 2019-2023 | |
| Kestra Medical Technology Services, INC. | $55.36 | 2022 | |
| Becton, Dickinson and Company | $53.00 | 2024 | Site-Rite |
| Amarin Pharma, INC. | $37.19 | 2021-2022 | |
| Philips North America LLC | $31.25 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $30.21 | 2021 | |
| Alnylam Pharmaceuticals INC. | $28.58 | 2024 | Amvuttra |
| Heartflow, INC. | $23.10 | 2025 | |
| Medtronic, INC. | $20.83 | 2025 | Symplicity G3 |
| Lexicon Pharmaceuticals, INC. | $20.83 | 2023 | Inpefa |
| Bridgebio Pharma, INC. | $20.02 | 2025 | Attruby |
| Chiesi USA, INC. | $15.71 | 2020 | |
| Vifor Pharma, INC. | $14.17 | 2019 | |
| Bardy Diagnostics, INC. | $7.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.